Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19214546 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | May 2025 | January 2026 | Allow | 8 | 2 | 0 | No | No |
| 19034336 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | January 2025 | December 2025 | Allow | 11 | 2 | 0 | No | No |
| 18752290 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | June 2024 | January 2025 | Allow | 7 | 0 | 1 | No | No |
| 18657650 | NOVEL COMPOUND AND APPLICATION THEREOF | May 2024 | August 2025 | Allow | 16 | 3 | 0 | Yes | No |
| 18640905 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | April 2024 | March 2025 | Allow | 11 | 1 | 0 | No | No |
| 18621742 | RNase Inhibitors | March 2024 | October 2025 | Allow | 18 | 1 | 0 | No | No |
| 18317177 | OLIGONUCLEOTIDE AND USE THEREOF AGAINST HEPATITIS B VIRUS AND HEPATITIS D VIRUS | March 2024 | December 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18582279 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | February 2024 | February 2025 | Allow | 12 | 2 | 0 | No | No |
| 18443300 | ANTISENSE OLIGONUCLEOTIDES TARGETING SCN2A FOR THE TREATMENT OF SCN1A ENCEPHALOPATHIES | February 2024 | January 2026 | Allow | 23 | 1 | 0 | No | No |
| 18441001 | COMPOSITIONS AND METHODS FOR INHIBITING TRANSMEMBRANE SERINE PROTEASE 6 (TMPRSS6) EXPRESSION | February 2024 | November 2025 | Allow | 21 | 1 | 1 | No | No |
| 18523743 | DIAGNOSTIC KIT FOR METASTASIS AND INVASION OF BREAST CANCER AND USE OF shRNA MOLECULE FOR SILENCING EXPRESSION OF HUMAN LINC01614 | November 2023 | March 2025 | Allow | 15 | 2 | 0 | No | No |
| 18523746 | Compounds and Methods for Reducing LRRK2 Expression | November 2023 | August 2024 | Allow | 9 | 0 | 0 | No | No |
| 18509899 | RNase Inhibitors | November 2023 | October 2025 | Allow | 23 | 1 | 0 | No | No |
| 18507175 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | November 2023 | May 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18503748 | MICELLAR NANOPARTICLES AND USES THEREOF | November 2023 | March 2026 | Abandon | 28 | 2 | 1 | No | No |
| 18383073 | ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | October 2023 | November 2025 | Allow | 25 | 2 | 1 | No | No |
| 18484291 | PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | October 2023 | May 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18374166 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE | September 2023 | October 2025 | Allow | 25 | 1 | 1 | No | No |
| 18473936 | ANTISENSE OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTION OR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA | September 2023 | December 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18346686 | NUCLEIC ACIDS ENCODING CRISPR-ASSOCIATED PROTEINS AND USES THEREOF | July 2023 | March 2025 | Allow | 20 | 0 | 1 | No | No |
| 18345407 | THERAPEUTIC OLIGONUCLEOTIDES | June 2023 | April 2025 | Allow | 21 | 1 | 1 | No | No |
| 18333007 | Selective Antisense Compounds and Uses Thereof | June 2023 | March 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18321996 | REGULATION OF GENE EXPRESSION THROUGH APTAMER-MODULATED POLYADENYLATION | May 2023 | October 2025 | Allow | 29 | 1 | 1 | No | No |
| 18314258 | RNA-Editing Oligonucleotides and Uses Thereof | May 2023 | August 2024 | Allow | 15 | 2 | 1 | No | No |
| 18130278 | METHODS AND COMPOSITIONS FOR TREATING A PREMATURE STOP CODON-MEDIATED DISORDER | April 2023 | December 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18187524 | METHODS FOR INTRACELLULAR DELIVERY AND ENHANCED GENE TARGETING | March 2023 | September 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18178206 | ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS | March 2023 | March 2025 | Allow | 24 | 2 | 1 | No | No |
| 18156231 | Novel Replicase Cycling Reaction (RCR) and the Related SamRNA Designs Thereof | January 2023 | March 2026 | Allow | 38 | 1 | 1 | No | No |
| 18146840 | Adeno-Associated Virus Vector Delivery of Muscle Specific Micro-Dystrophin to Treat Muscular Dystrophy | December 2022 | April 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18001853 | COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION | December 2022 | August 2025 | Allow | 32 | 0 | 0 | No | No |
| 18061371 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | December 2022 | March 2026 | Abandon | 40 | 1 | 0 | No | No |
| 18059606 | REGULATION OF GENE EXPRESSION VIA APTAMER-MEDIATED CONTROL OF SELF-CLEAVING RIBOZYMES | November 2022 | March 2025 | Allow | 28 | 1 | 1 | No | No |
| 18058664 | COMPLEMENT FACTOR B-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | November 2022 | February 2026 | Allow | 39 | 2 | 0 | Yes | No |
| 18054813 | DNA COMPOSITIONS AND RELATED METHODS | November 2022 | January 2025 | Allow | 26 | 4 | 1 | Yes | No |
| 18054113 | COMPLEMENT COMPONENT C1R INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME | November 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17924063 | Methods and Compositions for the ADAR-Mediated Editing of ABCA4 | November 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 18052785 | METHODS AND COMPOSITIONS FOR MACROPHAGE POLARIZATION | November 2022 | November 2025 | Allow | 36 | 4 | 1 | No | No |
| 17919611 | PD-1-specific antisense oligonucleotide and its use in therapy | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17918877 | METHOD AND DRUG FOR TREATING HURLER SYNDROME | October 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 18046235 | ANTISENSE THERAPEUTICS FOR THE TREATMENT OF CORONAVIRUS | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 18045109 | OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION | October 2022 | September 2025 | Allow | 36 | 2 | 1 | No | No |
| 17960090 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | October 2022 | March 2025 | Abandon | 29 | 1 | 1 | No | No |
| 17907189 | Aptamers That Bind Thiamine Analogs and Derivatives | September 2022 | November 2025 | Allow | 37 | 0 | 1 | Yes | No |
| 17912510 | GENE SILENCING AGENTS FOR TARGETING CORONAVIRUS GENES AND USES THEREOF | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17906500 | TREATMENT OF COVID-19 WITH REVERSE MICELLE SYSTEM COMPRISING UNMODIFIED OLIGONUCLEOTIDES | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17911665 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17911343 | COMPOSITIONS FOR THE TREATMENT OF NASH AND ASSOCIATED DISORDERS AND METHODS OF USING SAME | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17821693 | TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS | August 2022 | July 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17818858 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | August 2022 | November 2024 | Allow | 27 | 2 | 1 | No | No |
| 17760343 | MIRNA-485 INHIBITOR FOR GENE UPREGULATION | August 2022 | February 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17817874 | RNA-Editing Oligonucleotides and Uses Thereof | August 2022 | May 2025 | Allow | 33 | 1 | 1 | No | No |
| 17811961 | siRNA based on RNA sequence of SARS-CoV-2 and use thereof | July 2022 | September 2024 | Allow | 26 | 2 | 1 | No | No |
| 17851227 | Materials and Methods for Treatment of Myotonic Dystrophy Type 1 (DM) and Other Related Disorders | June 2022 | August 2025 | Abandon | 37 | 2 | 1 | Yes | No |
| 17846457 | INHIBITION OF POLYOMAVIRUS REPLICATION | June 2022 | July 2025 | Allow | 37 | 2 | 0 | Yes | No |
| 17784878 | Allele-Specific Silencing of Transforming Growth Factor Beta Induced Gene with R124H Mutation Using Short Interfering RNA | June 2022 | March 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17829801 | Treatment Of Cerebrovascular Disease With Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) Agents | June 2022 | September 2024 | Allow | 27 | 5 | 1 | No | No |
| 17748961 | MODULATORS OF GROWTH HORMONE RECEPTOR | May 2022 | March 2026 | Abandon | 46 | 1 | 0 | No | No |
| 17732757 | TREATMENT METHODS FOR MUSCULAR DYSTROPHY | April 2022 | January 2025 | Allow | 32 | 1 | 0 | No | No |
| 17768914 | SOLUTE CARRIER FAMILY MEMBER IRNA COMPOSITIONS AND METHODS OF USE THEREOF | April 2022 | August 2025 | Allow | 40 | 0 | 1 | No | No |
| 17688754 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | March 2022 | February 2026 | Abandon | 48 | 1 | 0 | No | No |
| 17680940 | Treatment Of Liver Disease With Mitochondrial Glycerol-3-Phosphate Acyltransferase (GPAM) Inhibitors | February 2022 | September 2024 | Allow | 31 | 3 | 1 | No | No |
| 17648340 | Novel RNA Composition and Production Method for Use in iPS Cell Generation | January 2022 | December 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17570714 | MICRORNAS FOR CARDIAC REGENERATION THROUGH INDUCTION OF CARDIAC MYOCYTE PROLIFERATION | January 2022 | April 2025 | Allow | 39 | 3 | 1 | No | No |
| 17623569 | NOVEL COMPOUND AND APPLICATION THEREOF | December 2021 | April 2025 | Allow | 39 | 2 | 1 | Yes | No |
| 17621449 | ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA | December 2021 | October 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17548995 | COMPOSITION FOR DELIVERY OF GENETIC MATERIAL | December 2021 | November 2025 | Abandon | 47 | 3 | 1 | No | No |
| 17544984 | SERUM AMYLOID P COMPONENT (APCS) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | December 2021 | December 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17529119 | Compound for treatment of heart failure | November 2021 | December 2025 | Allow | 49 | 5 | 1 | No | No |
| 17522754 | COMPOSITIONS FOR DELIVERY OF CODON-OPTIMIZED MRNA | November 2021 | November 2025 | Allow | 48 | 4 | 1 | Yes | No |
| 17594740 | OLIGOMERIC NUCLEIC ACID MOLECULE, AND APPLICATION THEREOF IN AN ACUTE INTERMITTENT PORPHYRIA TREATMENT | October 2021 | December 2025 | Allow | 50 | 1 | 1 | No | No |
| 17607102 | APTAMER NUCLEIC ACID MOLECULE, AND COMPLEX AND APPLICATION THEREOF | October 2021 | January 2026 | Allow | 51 | 0 | 1 | No | No |
| 17605908 | DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES WITH SHORTENED SENSE STRANDS | October 2021 | October 2025 | Allow | 48 | 2 | 1 | No | No |
| 17604510 | METHODS FOR THE TREATMENT AND PROGNOSIS OF CANCER | October 2021 | July 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17489357 | NOVEL MRNA COMPOSITION AND PRODUCTION METHOD FOR USE IN ANTI-VIRAL AND ANTI-CANCER VACCINES | September 2021 | November 2025 | Allow | 50 | 5 | 0 | No | No |
| 17471719 | GAPMER ANTISENSE OLIGONUCLEOTIDES TARGETING SARS-COV-2 FOR TREATING COVID 19 | September 2021 | July 2024 | Allow | 34 | 3 | 1 | No | No |
| 17437507 | COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION | September 2021 | November 2024 | Allow | 38 | 0 | 0 | No | No |
| 17437123 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING FVIII THERAPEUTICS | September 2021 | February 2025 | Allow | 41 | 0 | 1 | No | No |
| 17371935 | 5'-CAP COMPOUNDS AND THEIR USES IN STABILIZING RNA, EXPRESSING PROTEINS AND IN THERAPY | July 2021 | December 2024 | Abandon | 41 | 6 | 1 | Yes | Yes |
| 17372173 | MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS | July 2021 | March 2024 | Allow | 33 | 6 | 0 | No | No |
| 17420460 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | July 2021 | August 2024 | Allow | 38 | 0 | 0 | No | No |
| 17339366 | P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION | June 2021 | January 2025 | Allow | 44 | 4 | 0 | No | No |
| 17319391 | CCR7 APTAMERS AND USES THEREOF | May 2021 | August 2024 | Allow | 40 | 2 | 0 | No | No |
| 17314962 | SYSTEMS AND METHODS FOR USE OF ADENOSINE TRIPHOSPHATE (ATP) TO RELIEVE SYMPTOMS OF COVID-19 AND RELATED INFECTIONS | May 2021 | March 2025 | Allow | 46 | 3 | 0 | Yes | No |
| 17239461 | DISEASE STRATIFICATION OF LIVER DISEASE AND RELATED METHODS | April 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 16606433 | P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION | April 2021 | December 2025 | Abandon | 60 | 3 | 0 | Yes | No |
| 17211622 | NUCLEIC ACIDS FOR CELL RECOGNITION AND INTEGRATION | March 2021 | June 2025 | Allow | 51 | 1 | 1 | No | No |
| 17268590 | Inducing Proliferation of Cardiomyocytes and Therapeutic Uses Related Thereto | February 2021 | January 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17175156 | OLIGONUCLEOTIDES TARGETING FRATAXIN AND RELATED METHODS | February 2021 | January 2025 | Allow | 47 | 3 | 1 | Yes | Yes |
| 17258544 | METHODS FOR TARGETING PAIN DIRECTED AT METABOLIC PATHWAYS | January 2021 | July 2024 | Allow | 42 | 0 | 1 | No | No |
| 16973464 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | December 2020 | May 2025 | Abandon | 53 | 1 | 1 | No | No |
| 17048236 | GENE THERAPY FOR DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES | October 2020 | June 2025 | Allow | 56 | 2 | 1 | No | No |
| 17023003 | COMPOSITION FOR TEMPERATURE SENSORS INCLUDING GRAPHENE OXIDE, DNAZYME AND PNA AND TEMPERATURE SENSING METHOD USING THE SAME | September 2020 | September 2024 | Allow | 48 | 1 | 1 | No | No |
| 16980300 | 5'-CAP-TRINUCLEOTIDE- OR HIGHER OLIGONUCLEOTIDE COMPOUNDS AND THEIR USE IN STABILIZING RNA, EXPRESSING PROTEINS IN THERAPY | September 2020 | January 2025 | Allow | 52 | 3 | 1 | Yes | No |
| 16971626 | CANCER THERAPEUTIC TARGETING USING MUTANT P53-SPECIFIC SIRNAS | August 2020 | August 2025 | Allow | 60 | 2 | 1 | No | No |
| 16969897 | POLYRIBONUCLEOTIDE CONTAINING DEUTERATED NUCLEOTIDES | August 2020 | September 2025 | Allow | 60 | 5 | 0 | Yes | Yes |
| 16963583 | METHOD OF INTRODUCING AN mRNA MOLECULE INTO A CELL | July 2020 | November 2024 | Allow | 52 | 2 | 1 | Yes | No |
| 16960508 | IMMUNE-ENHANCING RNAS FOR COMBINATION WITH CHIMERIC ANTIGEN RECEPTOR THERAPY | July 2020 | September 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16896811 | METHODS OF IMPROVING ADENO-ASSOCIATED VIRAL TRANSDUCTION | June 2020 | September 2024 | Allow | 52 | 5 | 0 | Yes | No |
| 16626395 | ANTISENSE OLIGONUCLEOTIDES FOR MODULATING THE FUNCTION OF A T CELL | December 2019 | August 2024 | Allow | 56 | 4 | 1 | No | No |
| 15974941 | TRANSCRIPTOMIC INDEX FOR CHARACTERIZING THE CELLULAR REPAIR RESPONSE AFTER SOFT TISSUE INJURY IN DIARTHRODIAL JOINTS | May 2018 | January 2025 | Allow | 60 | 5 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner POLIAKOVA-GEORGAN, EKATERINA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner POLIAKOVA-GEORGAN, EKATERINA works in Art Unit 1637 and has examined 54 patent applications in our dataset. With an allowance rate of 85.2%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 46 months.
Examiner POLIAKOVA-GEORGAN, EKATERINA's allowance rate of 85.2% places them in the 61% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by POLIAKOVA-GEORGAN, EKATERINA receive 2.33 office actions before reaching final disposition. This places the examiner in the 66% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by POLIAKOVA-GEORGAN, EKATERINA is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +4.5% benefit to allowance rate for applications examined by POLIAKOVA-GEORGAN, EKATERINA. This interview benefit is in the 28% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 22.7% of applications are subsequently allowed. This success rate is in the 29% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 57.1% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.9% of allowed cases (in the 74% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.